BioLineRx, Ltd. (BLRX.TA)


Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
359.00-0.90 (-0.25%)
At close: 10:24 AM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open348.00
Prev Close359.90
Bid359.00 x 255900
Ask359.80 x 42900
Day's Range348.00 - 366.00
52wk Range2.88 - 366.00
1y Target EstN/A
Market Cap20.26B
P/E Ratio (ttm)-1,581.50
BetaN/A
Volume491,644
Avg Vol (3m)63,624
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • PR Newswire2 days ago

    BioLineRx and I-Bridge Capital Establish a New Drug Development Joint Venture in China

    BioLineRx Ltd. (NASDAQ/TASE:BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that it has established a joint venture (JV) with I-Bridge Capital, a Chinese venture capital fund focused on developing innovative therapies in China. The joint venture, named iPharma, will develop innovative clinical and pre-clinical therapeutic candidates originating primarily in Israel to serve the Chinese and global healthcare markets.

  • PR Newswire16 days ago

    BioLineRx Reports Second Quarter 2016 Financial Results

    TEL AVIV, Israel, Aug. 11, 2016 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic ...

  • PR Newswire16 days ago

    BioLineRx Names Philip A. Serlin as Chief Executive Officer

    TASE: BLRX), a clinical stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that Philip A. Serlin has been named Chief Executive Officer of BioLineRx, effective October 10, 2016. Mr. Serlin joined the Company in 2009 as its Chief Financial and Operating Officer.